A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Journal of Nuclear Medicine · 2023-05 · 64 (5) · 744-750
DOI: 10.2967/jnumed.122.264448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.11.2022. Verfasst von Heying Duan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Targeting of lesions seen on multiparametric MRI (mpMRI) improves prostate cancer (PC) detection at biopsy. However, 20%-65% of highly suspicious lesions on mpMRI (PI-RADS [Prostate Imaging-Reporting and Data System] 4 or 5) are false-positives (FPs), while 5%-10% of clinically significant PC (csPC) are missed. Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors (GRPRs) are both overexpressed in PC. We therefore aimed to evaluate the potential of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for biopsy guidance in patients with suspected PC.
Methods
A highly selective cohort of 13 men, aged 58.0 ± 7.1 y, with suspected PC (persistently high prostate-specific antigen [PSA] and PSA density) but negative or equivocal mpMRI results or negative biopsy were prospectively enrolled to undergo 68Ga-PSMA11 and 68Ga-RM2 PET/MRI. PET/MRI included whole-body and dedicated pelvic imaging after a delay of 20 min. All patients had targeted biopsy of any lesions seen on PET followed by standard 12-core biopsy. The SUVmax of suspected PC lesions was collected and compared with gold standard biopsy.
Results
PSA and PSA density at enrollment were 9.8 ± 6.0 (range, 1.5-25.5) ng/mL and 0.20 ± 0.18 (range, 0.06-0.68) ng/mL2, respectively. Standardized systematic biopsy revealed a total of 14 PCs in 8 participants: 7 were csPC and 7 were nonclinically significant PC (ncsPC). 68Ga-PSMA11 identified 25 lesions, of which 11 (44%) were true-positive (TP) (5 csPC). 68Ga-RM2 showed 27 lesions, of which 14 (52%) were TP, identifying all 7 csPC and also 7 ncsPC. There were 17 concordant lesions in 11 patients versus 14 discordant lesions in 7 patients between 68Ga-PSMA11 and 68Ga-RM2 PET. Incongruent lesions had the highest rate of FP (12 FP vs. 2 TP). SUVmax was significantly higher for TP than FP lesions in delayed pelvic imaging for 68Ga-PSMA11 (6.49 ± 4.14 vs. 4.05 ± 1.55, P = 0.023) but not for whole-body images, nor for 68Ga-RM2.
Conclusion
Our results show that 68Ga-PSMA11 and 68Ga-RM2 PET/MRI are feasible for biopsy guidance in suspected PC. Both radiopharmaceuticals detected additional clinically significant cancers not seen on mpMRI in this selective cohort. 68Ga-RM2 PET/MRI identified all csPC confirmed at biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California.
- Division of Body MRI, Department of Radiology, Stanford University, Stanford, California.
- Department of Urology, Stanford University, Stanford, California; and.
- Department of Pathology, Stanford University, Stanford, California.
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; aiagaru@stanford.edu.
Zitieren
APA
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., Aparici, C. M., Davidzon, G. A., Moradi, F., Sonn, G. A., & Iagaru, A. (2023). A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine, 64(5), 744-750. https://doi.org/10.2967/jnumed.122.264448
Vancouver
Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Kunder C, et al. A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine. 2023;64(5):744-750. doi:10.2967/jnumed.122.264448
BibTeX
@article{Duan2023,
author = {Duan, Heying and Ghanouni, Pejman and Daniel, Bruce and Rosenberg, Jarrett and Thong, Alan and Kunder, Christian and Aparici, Carina Mari and Davidzon, Guido A and Moradi, Farshad and Sonn, Geoffrey A and Iagaru, Andrei},
title = {A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {5},
pages = {744--750},
doi = {10.2967/jnumed.122.264448}
}
EUVIMED